Remicade (also known by its generic name infliximab) is an anti-TNF-alpha drug that was approved by the FDA in May 2005 to treat psoriatic arthritis and in September 2006 to treat chronic severe psoriasis. It is also approved for ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and Crohn's disease.
For patients with psoriasis or psoriatic arthritis, Remicade is administered in a doctor's office via intravenous infusion at 0, 2, and 6 weeks, then every 8 weeks.
To learn more, please visit the Remicade website.
Biosimilars for Remicade
A biosimilar is a medication that is highly similar to an existing FDA-approved biologic medicine (aka reference product). Biosimilars have the same strength, dosage, potential benefits, and side effects as the reference product and are administered the same way. Biosimilars still must be FDA-approved.
